Ipamorelin (5mg)
Improves Lean Body Mass
550.000 ₫
Delivery method:
Single vial
550.000 ₫
Ipamorelin pen (5mg/10mg)
715.000 ₫
Ipamorelin is the cleanest GHRP available — the only one documented to produce zero effect on cortisol, prolactin or aldosterone at clinical doses, and the only GHRP without appetite stimulation or meaningful receptor desensitisation over long use. That selectivity is why it is the most-recommended default in the clinical peptide literature and why it is the partner peptide in the Foundation, Core and Cutting stacks. The trade-off is modesty of effect: the acute GH pulse it produces is smaller than GHRP-2, GHRP-6 or Hexarelin. The strength comes from pairing — GHRH + Ipamorelin produces a GH release 3–5× greater than either alone (Bowers, JCEM) without the side-effect profile of stronger GHRPs. Dosed 200–300mcg nightly. Available as 5mg or 10mg vials.
Dosage
Start 0.1mg (100µg) once nightly; after 1 week double the daily total to 0.1mg twice daily — never exceed 100µg per single dose
Duration of effect
Pulses GH overnight; benefits build over weeks (plasma half-life: ~2 hours)
See full half-life table →Key Features
- Clean GH release
- No hunger increase
- Improved sleep
- Lean mass gains
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: European Journal of Endocrinology - ResearchGate
Clinical Research
Ipamorelin is the first selective growth hormone secretagogue, stimulating GH release with selectivity similar to GHRH without affecting ACTH or cortisol.
Read full studyAdditional Research
Source: García-del-Barco-Herrera et al., Clin Med Insights Cardiol (2017)
Comprehensive open-access review of the GHRP class summarising human clinical pharmacology data — including ipamorelin's selective GH release without elevation of cortisol, prolactin or appetite — the basis of its 'clean pulse' reputation.
Read full studyHuman Clinical Trials
- Ipamorelin after bowel surgeryInternational Journal of Colorectal Disease · 2014
Randomised placebo-controlled trial in 117 patients: faster recovery of gut function after bowel resection.
Read the trial117participants